Breaking Finance News

Amryt Pharma (LON:AMYT) target maintained at 65.00GBX, released a ratings update earlier today by Beaufort Securities

Beaufort Securities hold steady the target price of Amryt Pharma (LON:AMYT) at 65.00GBX reporting a possible upside of 2.44%.

Previously on Friday September 22, 2017, Beaufort Securities released a statement about Amryt Pharma (LON:AMYT) held steady the target price at 65.00GBX. At the time, this indicated a possible upside of 1.99%.

Just yesterday Amryt Pharma (LON:AMYT) traded 1.15% higher at 18.88GBX. Amryt Pharma’s 50-day moving average is 22.12GBX and its 200-day moving average is 22.51GBX. The last stock price is down -2.24% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.02% over the same time period. 10,000 shares of AMYT traded hands, down from an average trading volume of 134,803

Recent Performance Chart

Amryt Pharma (LON:AMYT)

Amryt Pharma has 52 week low of 13.44GBX and a 52 week high of 29.50GBX and has a market capitalization of 0 GBX.

In addition to Beaufort Securities reporting its stock price target, a total of 1 broker has issued a research note on the company. The average stock price target is 42.06GBX with 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally zero analysts rating the company a sell.

More About Amryt Pharma (LON:AMYT)

Amryt Pharma plc is a commercial-stage specialty pharmaceutical company focused on developing and delivering treatments for patients with rare and orphan diseases. The Company is building a diversified portfolio of proprietary drugs to help address some of rare and debilitating illnesses. The Company's lead products include AP 101 and AP102. AP101 (Episalvan) is a potential treatment for Epidermolysis Bullosa (EB), and it is in Phase III clinical trials. AP102 is focused on developing novel, next generation somatostatin analogue (SSA) peptide medicines for patients with rare neuroendocrine diseases. The Company holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union (EU) and other territories, including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia, which impairs the body's ability to remove LDL cholesterol (bad cholesterol) from the blood.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.